menu
    • menu
    [{"orgOrder":0,"company":"Polyrizon","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"N-Acylethanolamine","moa":"||CB2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Polyrizon \/ Polyrizon","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Polyrizon"},{"orgOrder":0,"company":"Polyrizon","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"N-Acylethanolamine","moa":"||CB2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Polyrizon \/ Polyrizon","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Polyrizon"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Polyrizon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Inapplicable"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Polyrizon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Inapplicable"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Eurofins CDMO","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"PL-14","moa":"IL-8 secretion","graph1":"Immunology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Polyrizon \/ Eurofins CDMO","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Eurofins CDMO"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Polyrizon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Inapplicable"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Polyrizon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Inapplicable"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PL-14","moa":"IL-8 secretion","graph1":"Immunology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Polyrizon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Polyrizon

    Menu

    Polyrizon

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Polyrizon Eyes $3.15B Epilepsy Market with Rescue Drug in Preclinical Stage

                            Details : Intranasal Benzodiazepines (BZDs) is being developed by Polyrizon as a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 13, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PL-14

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Polyrizon Reports PL-14 Allergy Blocker Safe in Human Nasal Tissue Model

                            Details : PL 14 is an intranasal hydrogel allergy blocker being developed by Polyrizon using its platform technology for the treatment of allergy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 25, 2025

                            Lead Product(s) : PL-14

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Polyrizon Advances Preclinical Epilepsy Rescue Treatment Studies

                            Details : A preclinical study has been initiated for intranasal Benzodiazepines (BZDs), as a first-line treatment for acute repetitive seizures (ARS) and status epilepticus.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 25, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Polyrizon Begins Preclinical Trials for Intranasal Naloxone

                            Details : Polyrizon is advancing intranasal naloxone, which is currently being evaluated for the treatment of patients suffering from opioid overdose.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            March 13, 2025

                            Lead Product(s) : Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Polyrizon Begins Preclinical Intranasal Naloxone Study for Opioid Overdose Therapy

                            Details : Naloxone is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PL-14

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Eurofins CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Polyrizon Enters GMP Manufacturing Agreement for PL-14 Allergy Blocker Trial

                            Details : The collaboration will supply Clinical Trial Material for Polyrizon’s PL-14 allergy blocker, in preparation for a clinical trial.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 02, 2024

                            Lead Product(s) : PL-14

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Eurofins CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SCI-160,N-Acylethanolamine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : SciSparc

                            Deal Size : $6.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SciSparc Grants Rights For Pain Therapy in $6M Biotech Agreement

                            Details : Under the agreement, SciSparc out-licensed its SCI-160 program, an innovative, proprietary synthetic combination of cannabinoids and N- acylethanolamines, being developed for the treatment of pain.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $3.0 million

                            August 28, 2024

                            Lead Product(s) : SCI-160,N-Acylethanolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : SciSparc

                            Deal Size : $6.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed

                            Polyrizon

                            Israel arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SCI-160,N-Acylethanolamine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : SciSparc

                            Deal Size : $6.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SciSparc Signs Global Out-Licensing Deal For Pain Therapy Worth $3 Million

                            Details : SciSparc out-licenses its SCI-160 program for the treatment of pain to Polyrizon. SCI-160 is an innovative, proprietary synthetic combination of cannabinoids and N-acylethanolamines.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $3.0 million

                            August 19, 2024

                            Lead Product(s) : SCI-160,N-Acylethanolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : SciSparc

                            Deal Size : $6.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth